Sofosbuvir Hepcivir contract manufacturing bulk exporter supplier wholesaler

Hepcivir – Sofosbuvir Tablet

International Name :

Hepcivir

Active Ingredient :

Sofosbuvir

Manufacturer :

CIPLA LTD

Form :

Tablet

Packing :

28 Tab

Strength :

400mg

Tags:

Description

SOFOSBUVIR (HEPCIVIR) TABLET – TREATMENT FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

Antiviral medicine Hepcivir 400mg Tablet. It’s used to treat chronic hepatitis C virus (HCV) infection alongside other drugs. It works by reducing the amount of hepatitis C virus in the body and eliminating it from the blood over time.

Hepcivir 400mg Tablet should be taken according to your doctor’s instructions for dosage and duration. Even if you feel better, do not miss any doses and complete the entire course of treatment. It should be consumed with food and at a certain time. Take the missed dose as soon as possible.

USES OF SOFOSBUVIR (HEPCIVIR) TABLET

Chronic hepatitis C virus (HCV) infection

WORKS OF SOFOSBUVIR (HEPCIVIR) TABLET

Antiviral medicine Hepcivir 400mg Tablet. It works by reducing the amount of hepatitis C virus in the body and eliminating it from the blood over time.

SIDE EFFECTS OF SOFOSBUVIR (HEPCIVIR) TABLET

The majority of adverse effects do not necessitate medical treatment and will go away as your body adjusts to the medication. Consult your doctor if they persist or if you are concerned.

Fatigue
Nausea
Headache
Insomnia (difficulty in sleeping)
Anemia (low number of red blood cells)

WARNING & PRECAUTIONS

Driving

Hepcivir 400mg Tablet may induce negative effects that impair your driving ability.

When combined with other drugs for the treatment of hepatitis C infection, Hepcivir 400mg Tablet might cause dizziness and blurred vision, which can impair your ability to drive.

Kidney

In patients with severe kidney disease, Hepcivir 400mg Tablet should be taken with caution. Hepcivir 400mg Tablet dosage may need to be adjusted. Please seek medical advice.

There is little information on the use of Hepcivir 400mg Tablet in these individuals. In patients with mild to severe kidney disease, no dose adjustments are indicated.